Potassium Hydroxide → 4-(4-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzenesulfonamide

HRID 645689

Reaktionsgleichung

[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[C:12]4[CH:30]=[CH:29][N:28](S(C5C=CC(C)=CC=5)(=O)=O)[C:13]=4[N:14]=[C:15]([NH:17][C:18]4[CH:23]=[CH:22][C:21]([S:24]([NH2:27])(=[O:26])=[O:25])=[CH:20][CH:19]=4)[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1.[OH-].[K+]>O1CCOCC1>[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[C:12]4[CH:30]=[CH:29][NH:28][C:13]=4[N:14]=[C:15]([NH:17][C:18]4[CH:19]=[CH:20][C:21]([S:24]([NH2:27])(=[O:26])=[O:25])=[CH:22][CH:23]=4)[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1

Komponenten

Reaktionsbedingungen

Temperatur: 70 °C

Versuchsvorschrift

To a solution of 4-(4-(1H-indazol-6-ylamino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzenesulfonamide (105 mg, 0.18 mmol) in dioxane (5 mL), aq. 1N KOH (1.50 mL, 1.50 mmol) was added. The mixture was then heated at 70° C. for 4 h. before it was concentrated in vacuo. The residue was then acidified with acetic acid (HOAc) (2.0 mL) and purified by HPLC to give the title compound (15 mg). MS 421.1 (M+H) (Compound 11-1).

Aufarbeitung

concentrationwas concentrated in vacuo
custompurified by HPLC

Quellen und Nachweise

ORD-Eintrag: ord-4b20c94309334e139ad62b600d16009e
Quelldatensatz: uspto-grants-2010_04
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US07705004B2

Verknüpfte Notizen

Wird geladen…